The ADDF offers funding to researchers in both nonprofit and for-profit organizations for drug discovery, clinical trials, and biomarker development. Visit our Research Priorities for specific information about our interests.



The majority of funding is provided through four Core Requests for Proposals (RFPs). Letters of intent are accepted and reviewed on a rolling basis during four cycles each year, with corresponding deadlines for invited full proposals. Check back throughout the year for additional funding opportunities through our collaborations with non-profit, government, and industry partners.

Read our policies on application submissions and funding for Core RFPs.


Program to Accelerate Clinical Trials (PACT) RFP

Seeks to support Phase 0 through Phase 2 clinical trials, experimental medicine studies in human subjects, and IND-enabling studies.


Biomarkers Development RFP

Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. Please note that peripheral biomarkers (including but not limited to modalities such as blood, saliva, urine, and ocular biomarkers) will no longer be considered through this RFP. If you are developing one of these biomarkers, please apply through the Diagnostics Accelerator: Peripheral Biomarkers RFP.


Prevention Beyond the Pipeline RFP

Seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.


Drug Discovery RFP

Seeks to support programs that advance novel lead molecules to the clinical candidate selection stage, or build preclinical evidence in relevant animal models for repurposed/repositioned drugs.




Diagnostics Accelerator: Peripheral Biomarkers RFP

Seeks to support proof-of-principle and validation studies for peripheral biomarkers and novel diagnostic technologies for Alzheimer's disease and related dementias. Funding and committed project support by from industry experts is provided through a collaboration between the ADDF, Bill Gates, and other partners.


Letter of Intent: September 14, 2018
Full Proposal: November 16, 2018


The Treat FTD Fund RFP

Supports clinical development of novel and repurposed drugs for FTD disorders through proof-of-concept and pilot proof-of-mechanism trials or phase 0/1 studies in healthy volunteers assessing pharmacodynamic outcomes. This program is in partnership with The Association for Frontotemporal Degeneration.


Letter of Intent: November 9, 2018
Full Proposal: February 15, 2019


ADDF-Harrington Scholar Program RFP

Seeks to support the preclinical development of new therapies by providing research funding and committed project support by a team of industry experts through a collaboration between the ADDF and Harrington Discovery Institute.




Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration.






ADDF/NIH Funding

Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.


Conference Funding

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email with a brief summary of your conference


Stay Updated on Upcoming Deadlines and RFP Announcements

Sign up to receive news by email.